{{مراجع|2|refs=<ref name=WHOList95>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95 | journal = WHO Drug Information | volume = 20 | issue = 2 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/20_2_2006_INN95.pdf | format=PDF}}</ref><ref name=WHOList90>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90 | journal = WHO Drug Information | volume = 18 | issue = 1 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_1_2004_INN90.pdf | format=PDF}}</ref><ref name=WHOList99>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99 | journal = WHO Drug Information | volume = 22 | issue = 2 | year = 2008 | url = http://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf | format=PDF}}</ref><ref name=WHOList98>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98 | journal = WHO Drug Information | volume = 21 | issue = 4 | year = 2007 | url = http://www.who.int/medicines/publications/druginformation/innlists/P-List98.pdf | format=PDF}}</ref><ref name=WHOList83>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83 | journal = WHO Drug Information | volume = 14 | issue = 2 | year = 2000 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_2_2000_INN-83.pdf | format=PDF}}</ref><ref name=Amatuximab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Amatuximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/amatuximab.pdf}}</ref><ref name=WHOList87>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87 | journal = WHO Drug Information | volume = 16 | issue = 2 | year = 2002 | url = http://whqlibdoc.who.int/druginfo/16_2_2002_INN87.pdf | format=PDF}}</ref><ref name=WHOList88>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88 | journal = WHO Drug Information | volume = 17 | issue = 1 | year = 2003 | url = http://whqlibdoc.who.int/druginfo/17_1_2003_INN88.pdf | format=PDF}}</ref><ref name=WHOList104>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf | format=PDF}}</ref><ref name=WHOList93>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93 | journal = WHO Drug Information | volume = 19 | issue = 2 | year = 2008 | url = http://whqlibdoc.who.int/druginfo/19_2_2005_INN93.pdf | format=PDF}}</ref><ref name=WHOList92>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92 | journal = WHO Drug Information | volume = 18 | issue = 4 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_4_2004_INN92.pdf | format=PDF}}</ref><ref name=WHOList105>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf | format=PDF}}</ref><ref name="Brentuximab vedotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Brentuximab vedotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/brentuximab-vedotin.pdf}}</ref><ref name=Briakinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Briakinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/briakinumab.pdf}}</ref><ref name=Brodalumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/brodalumab.pdf}}</ref><ref name=WHOList97>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97 | journal = WHO Drug Information | volume = 21 | issue = 2 | year = 2007 | url = http://whqlibdoc.who.int/druginfo/21_2_2007_INN97.pdf | format=PDF}}</ref><ref name=WHOList106>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 | journal = WHO Drug Information | volume = 25 | issue = 4 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf | format=PDF}}</ref><ref name=Carlumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/carlumab.pdf}}</ref><ref name="Clivatuzumab tetraxetan">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium-Y-90-clivatuzumab-tetraxetan.pdf}}</ref><ref name=Clazakizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Clazakizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/clazakizumab.pdf}}</ref><ref name=Crenezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Crenezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/crenezumab.pdf}}</ref><ref name=Dalotuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dalotuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dalotuzumab.pdf}}</ref><ref name=WHOList101>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101 | journal = WHO Drug Information | volume = 23 | issue = 2 | year = 2009 | url = http://whqlibdoc.who.int/druginfo/23_2_2009_INN101.pdf | format=PDF}}</ref><ref name=Alirocumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Alirocumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/alirocumab.pdf}}</ref><ref name=WHOList94>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94 | journal = WHO Drug Information | volume = 19 | issue = 4 | year = 2005 | url = http://whqlibdoc.who.int/druginfo/19_4_2005_INN94.pdf | format=PDF}}</ref><ref name=Demcizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Demcizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/demcizumab.pdf}}</ref><ref name=WHOList66>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66 | journal = WHO Drug Information | volume = 5 | issue = 4 | year = 1991 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list66.pdf | format=PDF}}</ref><ref name=Actoxumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Actoxumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/actoxumab.pdf}}</ref><ref name=Drozitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/drozitumab.pdf}}</ref><ref name=Bezlotoxumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Bezlotoxumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/bezlotoxumab.pdf}}</ref><ref name=WHOList107>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 | journal = WHO Drug Information | volume = 26 | issue = 2 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf | format=PDF}}</ref><ref name=Dupilumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dupilumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dupilumab.pdf}}</ref><ref name=WHOList85>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85 | journal = WHO Drug Information | volume = 15 | issue = 2 | year = 2001 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_15_2_2001_INN-85.pdf | format=PDF}}</ref><ref name=Dusigitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dusigitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dusigitumab.pdf}}</ref><ref name=Enavatuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/enavatuzumab.pdf}}</ref><ref name=WHOList77>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77 | journal = WHO Drug Information | volume = 11 | issue = 2 | year = 1997 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf | format=PDF}}</ref><ref name=Enokizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enokizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/enokizumab.pdf}}</ref><ref name=Ensituximab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ensituximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ensituximab.pdf}}</ref><ref name=WHOList51>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 51 | journal = WHO Drug Information | volume = 18 | issue = 1 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf | format=PDF}}</ref><ref name="ALD518">{{cite news|url=http://www.genengnews.com/news/bnitem.aspx?name=68068627&source=genwire|title=BMS Shells Out $85M Up Front for Alder’s Mid-Stage Rheumatoid Arthritis Antibody|date=10 November 2009|publisher=Genetic Engineering & Biotechnology News}}</ref><ref name=WHOList84>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84 | journal = WHO Drug Information | volume = 14 | issue = 4 | year = 2000 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_4_2000_INN-84.pdf | format=PDF}}</ref><ref name="IMA-638">{{cite web |url=http://www.wyeth.com/research/projects |title=Wyeth.com {{!}} Complete Project Listing | year = 2008 |publisher = [[Wyeth]]|accessdate=November 19, 2008 |archiveurl = http://web.archive.org/web/20080612044330/http://www.wyeth.com/research/projects |archivedate = June 12, 2008}}</ref><ref name=Etrolizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Etrolizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/etrolizumab.pdf}}</ref><ref name=Ch1418>{{cite web|url=http://www.sec.gov/Archives/edgar/data/1082554/000104746911001229/a2202121z10-k.htm#da77001_item_1._business|title=United Therapeutics 10-K report|accessdate=5 November 2011}}</ref><ref name=WHOList108>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108 | journal = WHO Drug Information | volume = 26 | issue = 4 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL108_Final.pdf | format=PDF}}</ref><ref name=WHOList91>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91 | journal = WHO Drug Information | volume = 18 | issue = 2 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf | format=PDF}}</ref><ref name=WHOList86>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86 | journal = WHO Drug Information | volume = 16 | issue = 12 | year = 2002 | url = http://whqlibdoc.who.int/druginfo/16_1_2002_INN86.pdf | format=PDF}}</ref><ref name=Fasinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fasinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/fasinumab.pdf}}</ref><ref name=Fezakinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/fezakinumab.pdf}}</ref><ref name=NCT00883896>{{ClinicalTrialsGov|NCT00883896|Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis}}</ref><ref name=NCT00563524>{{ClinicalTrialsGov|NCT00563524|Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis}}</ref><ref name=Ficlatuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ficlatuzumab.pdf}}</ref><ref name=Flanvotumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/flanvotumab.pdf}}</ref><ref name=WHOList103>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103 | journal = WHO Drug Information | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/INN_PL103.pdf | format=PDF}}</ref><ref name=WHOList56>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56 | journal = WHO Drug Information | volume = 20 | issue = 3 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/INN_2006_list56.pdf | format=PDF}}</ref><ref name=Fresolimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fresolimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/fresolimumab.pdf}}</ref><ref name=Fulranumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/fulranumab.pdf}}</ref><ref name=Ganitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ganitumab.pdf}}</ref><ref name=Gevokizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Gevokizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/gevokizumab.pdf}}</ref><ref name=WHOList102>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 102 | journal = WHO Drug Information | volume = 23 | issue = 4 | year = 2009 | url = http://www.who.int/medicines/services/inn/FINAL_PL102.pdf | format=PDF}}</ref><ref name="Glembatumumab">[[National Cancer Institute|NCI]] Drug Dictionary: [http://www.cancer.gov/drugdictionary/?CdrID=599456 Glemtumumab vedotin]</ref><ref name=GS6624>{{cite web|url=http://edgar.sec.gov/Archives/edgar/data/882095/000119312511050041/d10k.htm|title=Gilead Sciences 10-K report|accessdate=5 November 2011}}</ref><ref name=Icrucumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/icrucumab.pdf}}</ref><ref name=Intetumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/intetumumab.pdf}}</ref><ref name=NCT00537381>{{ClinicalTrialsGov|NCT00537381|A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer}}</ref><ref name=NCT00246012>{{ClinicalTrialsGov|NCT00246012|A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma}}</ref><ref name=Ixekizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ixekizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ixekizumab.pdf}}</ref><ref name=Lebrikizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Lebrikizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/lebrikizumab.pdf}}</ref><ref name=Mavrilimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/mavrilimumab.pdf}}</ref><ref name=Mogamulizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Mogamulizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/mogamulizumab.pdf}}</ref><ref name=WHOList96>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96 | journal = WHO Drug Information | volume = 20 | issue = 4 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/20_4_2006_INN96.pdf | format=PDF}}</ref><ref name="Moxetumomab pasudotox">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Moxetumomab Pasudotox|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/moxetumomab-pasudotox.pdf}}</ref><ref name=Narnatumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/narnatumab.pdf}}</ref><ref name=WHOList100>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy) | journal = WHO Drug Information | year = 2008 | url = http://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf | format=PDF}}</ref><ref name=Nesvacumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Nesvacumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/nesvacumab.pdf}}</ref><ref name=Nivolumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Nivolumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/nivolumab.pdf}}</ref><ref name=Ocaratuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ocaratuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ocaratuzumab.pdf}}</ref><ref name=Onartuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/onartuzumab.pdf}}</ref><ref name=Oxelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/oxelumab.pdf}}</ref><ref name=Ozanezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ozanezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ozanezumab.pdf}}</ref><ref name=Ozoralizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ozoralizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ozoralizumab.pdf}}</ref><ref name=Pidilizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Pidilizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/pidilizumab.pdf}}</ref><ref name=Placulumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Placulumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/placulumab.pdf}}</ref><ref name=Ponezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ponezumab.pdf}}</ref><ref name=Rilotumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/rilotumumab.pdf}}</ref><ref name=Romosozumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Romosozumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/romosozumab.pdf}}</ref><ref name=Rontalizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Rontalizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/rontalizumab.pdf}}</ref><ref name=Samalizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/samalizumab.pdf}}</ref><ref name=Sarilumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/sarilumab.pdf}}</ref><ref name=Secukinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Secukinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/secukinumab.pdf}}</ref><ref name=Sifalimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/sifalimumab.pdf}}</ref><ref name=Sirukumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/sirukumab.pdf}}</ref><ref name=Tabalumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tabalumab.pdf}}</ref><ref name=Teprotumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Teprotumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/teprotumumab.pdf}}</ref><ref name=Tildrakizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tildrakizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tildrakizumab.pdf}}</ref><ref name=Tralokinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tralokinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tralokinumab.pdf}}</ref><ref name=Urelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/urelumab.pdf}}</ref><ref name="Vorsetuzumab mafodotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Vorsetuzumab Mafodotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/vorsetuzumab_mafodotin.pdf}}</ref><ref name=Eldelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Eldelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/eldelumab.pdf}}</ref>{{مراجع|2|refs=<ref name=WHOList95>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95 | journal = WHO Drug Information | volume = 20 | issue = 2 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/20_2_2006_INN95.pdf | format=PDF}}</ref><ref name=WHOList90>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90 | journal = WHO Drug Information | volume = 18 | issue = 1 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_1_2004_INN90.pdf | format=PDF}}</ref><ref name=WHOList99>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99 | journal = WHO Drug Information | volume = 22 | issue = 2 | year = 2008 | url = http://www.who.int/entity/medicines/publications/druginformation/issues/INN-PList-No99.pdf | format=PDF}}</ref><ref name=WHOList98>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98 | journal = WHO Drug Information | volume = 21 | issue = 4 | year = 2007 | url = http://www.who.int/medicines/publications/druginformation/innlists/P-List98.pdf | format=PDF}}</ref><ref name=WHOList83>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83 | journal = WHO Drug Information | volume = 14 | issue = 2 | year = 2000 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_2_2000_INN-83.pdf | format=PDF}}</ref><ref name=Alirocumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Alirocumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/alirocumab.pdf}}</ref><ref name=Amatuximab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Amatuximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/amatuximab.pdf}}</ref><ref name=WHOList87>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87 | journal = WHO Drug Information | volume = 16 | issue = 2 | year = 2002 | url = http://whqlibdoc.who.int/druginfo/16_2_2002_INN87.pdf | format=PDF}}</ref><ref name=WHOList88>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88 | journal = WHO Drug Information | volume = 17 | issue = 1 | year = 2003 | url = http://whqlibdoc.who.int/druginfo/17_1_2003_INN88.pdf | format=PDF}}</ref><ref name=Actoxumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Actoxumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/actoxumab.pdf}}</ref><ref name=WHOList104>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL104.pdf | format=PDF}}</ref><ref name=WHOList93>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93 | journal = WHO Drug Information | volume = 19 | issue = 2 | year = 2008 | url = http://whqlibdoc.who.int/druginfo/19_2_2005_INN93.pdf | format=PDF}}</ref><ref name=WHOList92>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92 | journal = WHO Drug Information | volume = 18 | issue = 4 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_4_2004_INN92.pdf | format=PDF}}</ref><ref name=Bezlotoxumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Bezlotoxumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/bezlotoxumab.pdf}}</ref><ref name=WHOList105>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105 | journal = WHO Drug Information | volume = 25 | issue = 2 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL105.pdf | format=PDF}}</ref><ref name="Brentuximab vedotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Brentuximab vedotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/brentuximab-vedotin.pdf}}</ref><ref name=Briakinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Briakinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/briakinumab.pdf}}</ref><ref name=Brodalumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/brodalumab.pdf}}</ref><ref name=WHOList97>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97 | journal = WHO Drug Information | volume = 21 | issue = 2 | year = 2007 | url = http://whqlibdoc.who.int/druginfo/21_2_2007_INN97.pdf | format=PDF}}</ref><ref name=WHOList106>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106 | journal = WHO Drug Information | volume = 25 | issue = 4 | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf | format=PDF}}</ref><ref name=Carlumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/carlumab.pdf}}</ref><ref name="ALD518">{{cite news|url=http://www.genengnews.com/news/bnitem.aspx?name=68068627&source=genwire|title=BMS Shells Out $85M Up Front for Alder’s Mid-Stage Rheumatoid Arthritis Antibody|date=10 November 2009|publisher=Genetic Engineering & Biotechnology News}}</ref><ref name=Clazakizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Clazakizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/clazakizumab.pdf}}</ref><ref name="IMA-638">{{cite web |url=http://www.wyeth.com/research/projects |title=Wyeth.com {{!}} Complete Project Listing | year = 2008 |publisher = [[Wyeth]]|accessdate=November 19, 2008 |archiveurl = http://web.archive.org/web/20080612044330/http://www.wyeth.com/research/projects |archivedate = June 12, 2008}}</ref><ref name="Clivatuzumab tetraxetan">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/yttrium-Y-90-clivatuzumab-tetraxetan.pdf}}</ref><ref name=Ch1418>{{cite web|url=http://www.sec.gov/Archives/edgar/data/1082554/000104746911001229/a2202121z10-k.htm#da77001_item_1._business|title=United Therapeutics 10-K report|accessdate=5 November 2011}}</ref><ref name=Crenezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Crenezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/crenezumab.pdf}}</ref><ref name=Dalotuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dalotuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dalotuzumab.pdf}}</ref><ref name=WHOList101>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101 | journal = WHO Drug Information | volume = 23 | issue = 2 | year = 2009 | url = http://whqlibdoc.who.int/druginfo/23_2_2009_INN101.pdf | format=PDF}}</ref><ref name=Demcizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Demcizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/demcizumab.pdf}}</ref><ref name=WHOList94>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94 | journal = WHO Drug Information | volume = 19 | issue = 4 | year = 2005 | url = http://whqlibdoc.who.int/druginfo/19_4_2005_INN94.pdf | format=PDF}}</ref><ref name=WHOList66>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66 | journal = WHO Drug Information | volume = 5 | issue = 4 | year = 1991 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list66.pdf | format=PDF}}</ref><ref name=Drozitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/drozitumab.pdf}}</ref><ref name=WHOList107>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107 | journal = WHO Drug Information | volume = 26 | issue = 2 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf | format=PDF}}</ref><ref name=Dupilumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dupilumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dupilumab.pdf}}</ref><ref name=Dusigitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Dusigitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/dusigitumab.pdf}}</ref><ref name=WHOList85>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85 | journal = WHO Drug Information | volume = 15 | issue = 2 | year = 2001 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_15_2_2001_INN-85.pdf | format=PDF}}</ref><ref name=Enavatuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/enavatuzumab.pdf}}</ref><ref name=WHOList77>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77 | journal = WHO Drug Information | volume = 11 | issue = 2 | year = 1997 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list77.pdf | format=PDF}}</ref><ref name=Enokizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enokizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/enokizumab.pdf}}</ref><ref name=Ensituximab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ensituximab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ensituximab.pdf}}</ref><ref name=WHOList51>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 51 | journal = WHO Drug Information | volume = 18 | issue = 1 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/INN_2004_list51.pdf | format=PDF}}</ref><ref name=WHOList84>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84 | journal = WHO Drug Information | volume = 14 | issue = 4 | year = 2000 | url = http://whqlibdoc.who.int/druginfo/DRUG_INFO_14_4_2000_INN-84.pdf | format=PDF}}</ref><ref name=Etrolizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Etrolizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/etrolizumab.pdf}}</ref><ref name=WHOList108>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108 | journal = WHO Drug Information | volume = 26 | issue = 4 | year = 2012 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL108_Final.pdf | format=PDF}}</ref><ref name=WHOList91>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91 | journal = WHO Drug Information | volume = 18 | issue = 2 | year = 2004 | url = http://whqlibdoc.who.int/druginfo/18_2_2004_INN91.pdf | format=PDF}}</ref><ref name=WHOList86>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86 | journal = WHO Drug Information | volume = 16 | issue = 12 | year = 2002 | url = http://whqlibdoc.who.int/druginfo/16_1_2002_INN86.pdf | format=PDF}}</ref><ref name=Fasinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fasinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/fasinumab.pdf}}</ref><ref name=Fezakinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/fezakinumab.pdf}}</ref><ref name=NCT00883896>{{ClinicalTrialsGov|NCT00883896|Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis}}</ref><ref name=NCT00563524>{{ClinicalTrialsGov|NCT00563524|Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis}}</ref><ref name=Ficlatuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ficlatuzumab.pdf}}</ref><ref name=Flanvotumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/flanvotumab.pdf}}</ref><ref name=WHOList103>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103 | journal = WHO Drug Information | year = 2011 | url = http://www.who.int/medicines/publications/druginformation/INN_PL103.pdf | format=PDF}}</ref><ref name=Fresolimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fresolimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/fresolimumab.pdf}}</ref><ref name=Fulranumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/fulranumab.pdf}}</ref><ref name=Ganitumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ganitumab.pdf}}</ref><ref name=Gevokizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Gevokizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/gevokizumab.pdf}}</ref><ref name=WHOList102>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 102 | journal = WHO Drug Information | volume = 23 | issue = 4 | year = 2009 | url = http://www.who.int/medicines/services/inn/FINAL_PL102.pdf | format=PDF}}</ref><ref name="Glembatumumab">[[National Cancer Institute|NCI]] Drug Dictionary: [http://www.cancer.gov/drugdictionary/?CdrID=599456 Glemtumumab vedotin]</ref><ref name=GS6624>{{cite web|url=http://edgar.sec.gov/Archives/edgar/data/882095/000119312511050041/d10k.htm|title=Gilead Sciences 10-K report|accessdate=5 November 2011}}</ref><ref name=Icrucumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/icrucumab.pdf}}</ref><ref name=Intetumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/intetumumab.pdf}}</ref><ref name=NCT00537381>{{ClinicalTrialsGov|NCT00537381|A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer}}</ref><ref name=NCT00246012>{{ClinicalTrialsGov|NCT00246012|A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma}}</ref><ref name=Ixekizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ixekizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ixekizumab.pdf}}</ref><ref name=Lebrikizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Lebrikizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/lebrikizumab.pdf}}</ref><ref name=Mavrilimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/mavrilimumab.pdf}}</ref><ref name=Mogamulizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Mogamulizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/mogamulizumab.pdf}}</ref><ref name="Moxetumomab pasudotox">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Moxetumomab Pasudotox|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/moxetumomab-pasudotox.pdf}}</ref><ref name=WHOList96>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96 | journal = WHO Drug Information | volume = 20 | issue = 4 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/20_4_2006_INN96.pdf | format=PDF}}</ref><ref name=Narnatumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/narnatumab.pdf}}</ref><ref name=WHOList56>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56 | journal = WHO Drug Information | volume = 20 | issue = 3 | year = 2006 | url = http://whqlibdoc.who.int/druginfo/INN_2006_list56.pdf | format=PDF}}</ref><ref name=WHOList100>{{cite journal | author = [[منظمة الصحة العالمية]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy) | journal = WHO Drug Information | year = 2008 | url = http://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf | format=PDF}}</ref><ref name=Nesvacumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Nesvacumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/nesvacumab.pdf}}</ref><ref name=Nivolumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Nivolumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/nivolumab.pdf}}</ref><ref name=Ocaratuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ocaratuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ocaratuzumab.pdf}}</ref><ref name=Onartuzumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/onartuzumab.pdf}}</ref><ref name=Oxelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/oxelumab.pdf}}</ref><ref name=Ozanezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ozanezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ozanezumab.pdf}}</ref><ref name=Ozoralizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ozoralizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ozoralizumab.pdf}}</ref><ref name=Pidilizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Pidilizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/pidilizumab.pdf}}</ref><ref name=Placulumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Placulumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/placulumab.pdf}}</ref><ref name=Ponezumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/ponezumab.pdf}}</ref><ref name=Rilotumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/rilotumumab.pdf}}</ref><ref name=Romosozumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Romosozumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/romosozumab.pdf}}</ref><ref name=Rontalizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Rontalizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/rontalizumab.pdf}}</ref><ref name=Samalizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/samalizumab.pdf}}</ref><ref name=Sarilumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/sarilumab.pdf}}</ref><ref name=Secukinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Secukinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/secukinumab.pdf}}</ref><ref name=Sifalimumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/sifalimumab.pdf}}</ref><ref name=Sirukumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/sirukumab.pdf}}</ref><ref name=Tabalumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tabalumab.pdf}}</ref><ref name=Teprotumumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Teprotumumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/teprotumumab.pdf}}</ref><ref name=Tildrakizumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tildrakizumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tildrakizumab.pdf}}</ref><ref name=Tralokinumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tralokinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tralokinumab.pdf}}</ref><ref name=Urelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/urelumab.pdf}}</ref><ref name="Vorsetuzumab mafodotin">{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Vorsetuzumab Mafodotin|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/vorsetuzumab_mafodotin.pdf}}</ref><ref name=Eldelumab>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Eldelumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/eldelumab.pdf}}</ref>
